Publications : 2011 – Present

2011

Saksena Twenty-five years of implantable defibrillator practice in the USA: are we ready for globalization Interv Card Electrophysiol. 2011 Jan;30(1):1-3

Saksena S, Lewalter T, Lüderitz B:Twenty years of interventional cardiac electrophysiology: Meeting future challenges with continuing innovations’ Interv Card Electrophysiol. 2011 Jun;31(1):1-2.

Nagarakanti R, Saksena S, Hettrick D, Koehler JL, Grammatico A, Padeletti: Progression of new onset to established persistent atrial fibrillation: an implantable device-based analysis with implications for clinical classification of persistent atrial fibrillation Interv Card Electrophysiol. 2011 Oct;32(1):7-15

Saksena S, Slee A, Waldo AL, Freemantle N, Reynolds M, Rosenberg Y, Rathod S, Grant S, Thomas E, Wyse DG: Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management): An Assessment of Individual Antiarrhythmic Drug Therapies Compared With Rate Control With Propensity Score-Matched Analyses. J Am Coll Cardiol 2011;58:1975–85

2012

Saksena S: Clinical trials of antiarrhythmic therapies and optimizing health care resource deployment: the need for a paradigm shift. J Interv Card Electrophysiol. 2012 Jan;33(1):1-3.

Saksena S: Letter to the Editor: Reply: J Am Coll Cardiol. 2012 Mar 13;59(11):1040-1. J Am Coll Cardiol 2011;58:1975–85

2013

Saksena S: Antiarrhythmic therapy—the paradigm shifts in 2012: will it be enough to result in improved health care policies? (editorial) Journal of Intervent. Card. Electrophysiol.2013:36 (1):1-2

Lau CP, Tachapong N, Chun-Chieh and the SAFE study group: Prospective Randomized Study to

Assess the Efficacy of Site and Rate of Atrial Pacing on Long-Term Progression of Atrial Fibrillation in Sick Sinus Syndrome: Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) Study: Circulation. 2013; 128: 687-693

Saksena S: Building Atrial Fibrillation Awareness: Is it Time to get Beyond the Top Line? J Atr Fibrillation. 2013 Jun 30;6(1):908

2014

Saksena S: Interactions of interventional therapies with individual diseases and their substrates: the next challenge in improving patient outcomes. (editorial) J. Intervent Card Electrophysiol. 2014: 39:1-2.

Shah AM, Shah SJ, Anand IS, Sweitzer NK, O’Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD; TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail. 2014 Jan;7(1):104-15

Nagarakanti R, Slee A, Saksena S.: Left atrial reverse remodeling and prevention of progression of atrial fibrillation with atrial resynchronization device therapy utilizing dual-site right atrial pacing in patients with atrial fibrillation refractory to antiarrhythmic drugs or catheter ablation. J Interv Card Electrophysiol. 2014 ;40(3):245-54

Pitt B, Pfeffer M, Assman SF et al for the TOPCAT investigators: Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014; 370:1383-1392

Lewalter T, Saksena S: Proceedings of the 7th International Symposium on Interventional Electrophysiology. Foreword. J Interv Card Electrophysiol. 2014 Sep;40(3):207.

2015

Saksena S: Patient care and physician conflicts of interest. (editorial) J. Intervent Card Electrophysiol. 42:1-2:20152016

Saksena S: Tailoring interventional arrhythmia therapy to individual patients: seeking the Art and the Science of Cardiac Electrophysiology in 2016. J Interv Card Electrophysiol. 2016 Jan;45(1):1-2.

Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O’Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016 Feb 1;37(5):455-62

Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, Kenwood CT, Solomon SD, Desai AS, Fang JC, McKinlay SA, Pitt BA, Pfeffer MA; TOPCAT Investigators. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail. 2016 Mar;9(3):e001937

Nagarakanti R, Saksena S: Three-dimensional mapping and intracardiac echocardiography in the treatment of sinoatrial nodal tachycardias. J Interv Card Electrophysiol. 2016 Jun;46(1):55-61

2018

Saksena S: Festina Lente – a curiously apt aphorism, for interventional cardiac electrophysiology in 2018. (Editorial) J Interv Card Electrophysiol. 2018 51:1:1-2

Saksena S, Slee A: Atrial fibrillation and its pernicious role in heart failure with preserved ejection fraction: a new frontier in interventional electrophysiology. J. Intervent. Card. Electrophysiol. 2018:51:89-90

Cikes M, Claggett B, Shah AM, Desai AS, Lewis M, Shah SJ, Anand IS, O’Meara E, Rouleau J, Sweitzer NK, Fang J, Saksena S, Pitt B, Pfeffer M, Solomon SD: Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction: The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. J. Am. Coll. Cardiol. – Hrt. Fail. 2018:689-697

Vijayaraman P, Chung MK, Dandamudi G, Upadhyay G, Krishnan K, Crossley G, Campbel Kl, Lee B, Saksena S, Fisher JD, Lakkireddy DJ: His Bundle Pacing J. Am. Coll. Cardiol. 2018: 72:927-947

Saksena S, Levy S: Agustin (Tino) Castellanos, Jr: The Journal Editors honor a gentleman and a scholar. J. Intervent. Card. Electrophysiol. 2018::532(3): 1-3 .

Saksena S, Slee A, Saad M: Atrial Resynchronization Therapy in Patients with Atrial Fibrillation and Heart Failure with and without Systolic Left Ventricular Dysfunction J. Intervent. Card. Electrophysiology 2018:53(1):9-18.

Saksena S: The Journal turns over a new page in 2019 (editorial): 2018, 53(3): 281–281

2019

Slee A, Saad M, Saksena S: Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction: J. Intervent. Card. Electrophysiol 2019: Sep;55(3):325-331

Hall JA et al: Medical Misinformation: Vet the message; (editorial) Journal of the American Heart Association: 2019:8: http://dx.doi.org/10.1161/JAHA.118.011838 . Republished in 65 cardiology journals

2020

Slee A, Saksena S: Impact of emergence of initial heart failure symptoms on clinical outcomes of atrial fibrillation patients In the AFFIRM Trial. American Heart Journal 2020:220: 1-11

Pillarisetti J, Maybrook R, Parikh V, Adabala N, Khalafi M, Reddy S, Bommana S, Lakkireddy P, Reddy MY, Gianni C, Gopinathannair R, Mohanty S, Di Biase L, Natale A, Saksena S, Lakkireddy D: Peri-procedural use of direct anticoagulation agents during cardiac device implantation: vitamin K antagonists vs direct oral anticoagulants. J Interv Card Electrophysiol. 2020: 58:141-146

2021

Saksena S, Natale A. In memoriam: John Joseph Gallagher: a founder and pioneer of modern clinical electrophysiology (March 3, 1943, to November 21, 2020). J Interv Card Electrophysiol. 2021 Mar;60(2):163-164

2022

Camm AJ, Blomström-Lundqvist C, Boriani G, Goette A, Kowey PR, Merino JL, Piccini JP, Saksena S, Reiffel JA.: AIM-AF A Physician Survey in the United States and Europe. J Am Heart Assoc. 2022 Mar 15;11(6):e023838. doi: 10.1161/JAHA.121.023838

Levy S, Steinbeck G, Santini L, Maceda DP, Kantharia BK, Saksena S, Cappato R: Management of atrial fibrillation: Two decades of progress A Scientific Statement from the European Cardiac Arrhythmia Society. J. Intervent, Card. Electrophysiol. 2022 65(1):1-40

2023

Saksena S, Slee A, Natale A, Lakkireddy D, Shah D, Di Biase L, Lewalter T, Santageli P: Atrial Fibrillation (AF) can adversely impact Heart Failure with Preserved Ejection Fraction (HFpEF) by its association with Heart Failure (HF) Progression and Mortality: A Post-Hoc Propensity Score Matched Analysis of the TOPCAT Americas Trial. Europace EP 2023:25:1-14.

Reiffel JA, Blomström-Lundqvist C, Boriani G, Goette A, Kowey PR, Merino JL, Piccini JP, Saksena S, Camm J:Real-world utilization of the pill-in-the-pocket method for terminating episodes of atrial fibrillation: data from the multinational Antiarrhythmic Interventions for Managing Atrial Fibrillation (AIM- AF) survey. Europace. 2023 Jun 2;25(6):

2024

Saksena S, Slee AE. Editorial commentary on: Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study. Practice Update website. : https://www.practiceupdate.com/content/amiodarone-and-pulmonary-toxicity-in-patients-with-atrial- fibrillation/159036/65/2/1. Accessed January 07, 2024

2025

Saksena S, Slee A: Rate versus rhythm control for atrial fibrillation with heart failure. Card. Electrophysiol. Clinics. 2025:17(1): 19-41.

Saksena S, Slee A, Nagarakanti R, Prakash S: Atrial Fibrillation & Heart Failure with preserved ejection fraction: Advances and Challenges. J. Cardiovasc. ElectrophysiolOct;36(10):2720-2745.: https://doi.org/ 10.1111/jce.16625

Saksena S, Ken-Opurum J, McKindley DS, Preblick R, Rashkin J,Aldaas OM, Sistla SSS, Hsu JS: Arrhythmia Recurrence and Rhythm Control Strategies After Catheter Ablation of Newly Diagnosed Atrial Fibrillation (ARRC-AF ) study. J. Am. Coll. Cardiol.EP 2025 Apr;11(4):763-775: www.jacc.org/doi/epdf/10.1016/j.jacep.2024.11.020

Saksena S, Slee a, Merino JL, Goette A, Boriani G, Kowey PR, Piccini JP, Reiffel JA, Blomstrom- Lundqvist C, Camm AJ: An internation physician survey of current ablation practices in atrial fibrillation: An AIM-AF sub study. Heart Rhythm 2025: 22(9): 2174-2182 September doi: 10.1016/ j.hrthm. 2024. 10.044

Fengsrud E, Blomström-Lundqvist C, Camm AJ, Goette A, Kowey PR, Merino JL, Piccini JP, Saksena S, Reiffel JA, Boriani G: Antiarrhythmic Drug Use in Atrial Fibrillation among different European Countries – as determined by a Physician Survey. International Journal of Cardiology: heart and Vasculature 2025 (in press) https://doi.org/10.1016/j.ijcha.2025.101709

Saksena S: In Memoriam: professor Peter Osypka. Heart Rhythm 2025 DOI: 10.1016/j.hrthm.2025.11.009

ABSTRACTS AND PRESENTATIONS

2011-Present

2011

Saksena S, Slee A, Liu T, Verma A, The Electrophysiology Research Foundation: Impact of Nonpharmacologic Therapies on Clinical Outcomes of a Rate Control Strategy: Implications for second generation outcomes driven therapies from the AFFIRM Trial. ECAS 2011 April; J Interv Card Electrophysiol. 2011:2

Saksena S, Slee A, Waldo AL, Reynolds M, Freemantle N, Rosenberg Y, Rathod S, Thomas E, Grant S, Wyse G, Electrophysiology Research Foundation: Cardiovascular Outcomes in the AFFIRM Trial: Assessment of individual therapies using propensity score matched analyses. Heart Rhythm. 2011 May; Vol 8, No 5, Issue 5S-S576, page S83, AB37-3

Slee A, Saksena S, Waldo A, Reynolds M, Freemantle N, Rosenberg Y, Grant S, Tomas E, Rathod S, Wyse G, Kuo E, The Electrophysiology Research Foundation: Cardiovascular Hospitalization Profiles in Patients With Atrial Fibrillation and Mortality: Is there a relationship? Heart Rhythm. 2011 May; Vol 8, No 5, Issue 5S-S576, page S123, P01-51

Slee A, Saksena S, Verma A, Liu T, The Electrophysiology Research Foundation: Cardiovascular Hospitalizations Vary With Recurrent Atrial Fibrillation: Insights from the AFFIRM Trial. Heart Rhythm. 2011 May; Vol 8, No 5, Issue 5S-S576, page S240, PO3-64

Saksena S, Nagarakanti R, The Electrophysiology Research Foundation: Progression From New Onset to Established Persistent Atrial Fibrillation (AF): Correlation the New Clinical AF Classification With Atrial Fibrillation Burden. Heart Rhythm. 2011 May; Vol 8, No 5, Issue 5S-S576, page S288, PO4-10

Slee A, Saksena S, Waldo AL, Reynolds M, Freemantle N, Rosenberg Y, Rathod S, Grant S, Thomas L, Kuo E, Wyse G, The Electrophysiology Research Foundation: Impact of Antiarrhythmic Strategy and Drug Choice on Outcomes in Patients with Atrial Fibrillation and Thyroid Disease: A propensity scores matched analysis of the AFFIRM Trial. Heart Rhythm. 2011 May; Vol 8, No 5, Issue 5S-S576, page S308, PO4-61

2012

Slee A, Saksena S, Waldo A, Freemantle N, Reynolds M, Rosenberg Y, Wyse G : Role of Gender in Cardiovascular Hospitalizations With Individual Antiarrhythmic Drugs for Rhythm Control in Atrial Fibrillation: A propensity score matching analysis of the AFFIRM Trial. Heart Rhythm 2012 May; Vol 9, Issue 5S S1-S564, pageS385, PO05-54

Saksena S, Slee A, Waldo A, Freemantle N, Reynolds M, Rosenberg Y, Wyse D: Cardiovascular Outcomes in Patients Presenting with Persistent Atrial Fibrillation Treated by Individual Antiarrhythmic Drugs for Rhythm Control: A propensity score matching analysis of the AFFIRM Trial. 2012 May; Vol 9, Issue 5S S1-S564, page S126, PO1-104

2013

Slee A, Saksena S, Nagarakanti R: Cardiovascular outcomes in atrial fibrillation are influenced by quantitative rather than qualitative achievement of sinus rhythm and antiarrhythmic drug selection. J Interv Card Electrophysiol (2013) 36 (Suppl 1):S10

Saksena S, Slee A, Nagarakanti R: Impact of sinus rhythm restoration on cardiovascular outcomes in atrial fibrillation is influenced by quantitative rather than qualitative achievement of sinus rhythm and antiarrhythmic drug selection. Heart Rhythm, 2013: Vol. 10, No. 5, May Supplement: S390: PO05-73

Saksena S, Nagarakanti R, Slee A: Regional Distribution of Mapped Stable Organized Tachyarrhythmias (“Rotors”) in Paroxysmal and Persistent Atrial Fibrillation: Presented at the Am. Heart Assoc. Scientific sessions. Circulation 2013: 128(22) :abstr 13636

Nagarakanti R, Slee A, Skadsberg Saksena S. Regional Onset of Atrial Fibrillation May Differ in Patients with Septal versus Left Atrial Triggers: A Biatrial Three-Dimensional Noncontact Mapping Analysis. Presented at the Am. Heart Assoc. Scientific sessions. Circulation 2013 : 128(22: abstr 13615

Pfeffer M, TOPCAT investigators: Treatment of Preserved Cardiac Function Heart Failure with Aldosterone Antagonist. Presented at the Late Breaking Clinical Trials, America Heart Association Scientific Sessions, November 2013. Circulation. 2013; 128: e240-e327. doi:10.1161/?CIR.0b013e31829e8776

2014

Slee A, Nagarakanti R, Saksena S: Thyroid Disease in Patients with Atrial Fibrillation Identifies a Higher Risk Subpopulation for Antiarrhythmic Drug Therapy : A Propensity Score Matching Analysis of the AFFIRM trial. J. Am. Coll. Cardiol. 2014 (in press)

Nagarakanti R, Slee A, Saksena S: Impact of gender in mapping of atrial tachyarrhythmias (“rotors”) during biatrial and three-dimensional noncontact mapping spontaneous atrial fibrillation in humans. Heart Rhythm 2014:11:S394

Nagarakanti R, Slee A, Saksena S: Electrophysiologic mapping identifies stable organized tachyarrhythmias (“rotors”) during spontaneous atrial fibrillation with systolic heart failure. Circulation 2014: Issue 2: 130:A13259

2015

Saksena S, April Slee, Marwan Saad, Rangadham Nagarakanti: Atrial Fibrillation “Burden” rather than a single Recurrence identifies risk of Adverse Cardiovascular Events on Antiarrhythmic Drugs: Further insights from the AFFIRM trial. J. Am. Coll. Cardiol. 201:65, Number 10_Supplement :A383

Saksena S, Saad M, Slee AE, Laharawani H, Nagarakanti R: Long term rhythm control and survival improves after dual site right atrial pacing combined with “background” antiarrhythmic therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction . Heart Rhythm 2015: 12: S86

Saksena S, Nagarakanti R, Slee AE: Long term durability of improved super responder rates with intracardiac echo guided cardiac resynchronization device implantation in systolic heart failure. Heart Rhythm 2015: 12: S475

2016

Saad M, Nairooz R; Elgendy IY, Mentias A, Elgendy AY, Barakat AF, Abuzaid A, Mahmoud AN, Sewani A Maskoun N, Saksena S: Efficacy and Safety of Cryoballoon versus Radiofrequency Ablation for Atrial Fibrillation: A Meta-analysis of Randomized Clinical Trials: Presented at the American heart Association Scientific Sessions, November 2016 Circulation 2016:134:abstrr 16802

2017

Slee A, Saad M, Saksena S: Heart failure progression and survival in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction: insights from an AFFIRM sub study Presented at the ECAS meeting 2017. J Interv Card Electrophysiol 2017:47: April : Supplement: DOI 10.1007/s10840-017-0231-0: 6-2. Abstract 7-14

Saad M, Slee A, Saksena S: Efficacy and safety of cryoballoon versus radiofrequency ablation for atrial fibrillation: an updated meta-analysis. Presented at the ECAS meeting 2017. J Interv Card Electrophysiol. 2017:47: April :Supplement: DOI 10.1007/s10840-017-0231-0: 6-2 Abstract 18-24

Saksena S, Slee AE, and Saad M: Rate and Rhythm Control Strategies in Atrial Fibrillation Patients with Heart Failure and Preserved or Reduced Left Ventricular Ejection Fraction: An AFFIRM sub study Presented at the Annual Scientific Sessions of the Heart Rhythm Society 2017. Heart Rhythm, Vol. 14, No. 5, May Supplement 2017: S124

2018

Slee A, Saksena S: Can heart failure development in atrial fibrillation patients be impacted by initial choice of treatment strategy? Presented at the ECAS meeting 2018.J. Intervent. Card. Electrophysiol. 2018: 51 (Suppl 1): S 54

Slee A, Saksena S: Is there a relationship between rhythm control and the development of heart failure. Presented at the Annual Congress of the European Society of Cardiology 2018.Eur. Ht. J. 2018

2019

Saksena S, Slee A: Impact Of Emergence Of Initial Heart Failure Symptoms On Clinical Outcomes Of Atrial Fibrillation Patients In the AFFIRM Trial. Presented at the Annual Scientific Sessions of the Heart Rhythm Society 2019. Heart Rhythm 2019:16(5) Supplement: S176

Saksena s, Slee A: Progression Of Heart Failure Differs In Patients With Atrial Fibrillation With Rate And Rhythm Control Strategies. Presented at the Annual Scientific Sessions of the Heart Rhythm Society 2019. Heart Rhythm 2019:16(5) Supplement: S410

2020

Saksena S, Slee A: Sudden Death In Heart Failure With Preserved Cardiac Function: A Treatment Of Preserved Cardiac Function Heart Failure (TOPCAT) Americas Trial Sub study : Presented at the Annual Scientific Sessions of the Heart Rhythm Society 2020: Heart Rhythm 2020:17(5):S38

Saksena S, Slee A: Antiarrhythmic Drug Therapy For Atrial Fibrillation Complicating Heart Failure With Preserved Cardiac Function: First Clinical Trial Experience From The Treatment Of Preserved Cardiac Function Heart Failure With An Aldosterone Antagonist (TOPCAT) Americas Trial Sub study :Presented at the Annual Scientific Sessions of the Heart Rhythm Society 2020: Heart Rhythm 2020:17(5) S80

Saksena S, Slee A: Loss Of Rhythm Control In Heart Failure With Preserved Systolic Function: Accelerates Mortality Due To Pump Failure. Presented at Heart Failure Association Annual Scientific Sessions, 2020: https://esc365.escardio.org/Congress/222585-loss-of-rhythm-control-in-heart-failure-with-preserved-systolic- function-accelerates-mortality-due-to-pump-failure

Saksena S, Slee A: Sudden Death In Heart Failure With Preserved Cardiac Function Presented at Heart Failure Association Annual Scientific Sessions, 2020: https://esc365.escardio.org/Congress/222742- sudden- death-in-heart-failure-with-preserved-cardiac-function

Saksena S, Slee A, Lakkireddy DJ, Shah D, DiBiase L, Lewalter, T, Natale A: Predictors of adverse cardiovascular outcomes in patients with atrial fibrillation and heart failure with preserved systolic function: a TOPCAT AMERICAS post hoc analysis (presented at the American Heart Association, Annual Scientific Sessions, 2020 Circulation Volume 142, Number Suppl_3 https://doi.org/10.1161/circ.142.suppl_3.15198

2021

Nagarakanti R, Saksena S, Slee A, Lakkireddy DJ, Shah DC, Di Biase L, Lewalter T, Santangelli S, Natale A. Atrial fibrillation is associated with worsening of heart failure and cardiovascular hospitalizations in HF with preserved EF in minorities and specific comorbidities. Moderated Poster presentation Presented at the Annual Scientific Sessions Heart Rhythm Society, Boston, MA, USA. Heart Rhythm abstract

Blomström-Lundqvist C, Camm AJ, Goette A, Kowey PR, Merino JL, Piccini JP, Reiffel JA, Saksena S, Boriani G. Antiarrhythmic interventions for managing atrial fibrillation (AIM-AF) study: a physician survey of antiarrhythmic drug and treatment practices and guideline adherence in Europe. Presented at the Annual Scientific Sessions, European Society of Cardiology 2021. Europace 2021:23 Supplement 3 :196

Piccini JP, Blomström-Lundqvist C, Boriani G, Goette A, Kowey PR, Merino JL, Reiffel JA, Saksena S, Camm AJ. Treatment of Patients with Atrial Fibrillation and Heart Failure in the AIM-AF (Antiarrhythmic Interventions for Managing Atrial Fibrillation) Study: A Physician Survey on the Prescription of Antiarrhythmic Drugs in the US and Europe. Presented at the Annual Scientific Sessions, American Heart Association, 2021. Circulation epub Circulation. 2021;144:A12766

Reiffel JA, Blomström-Lundqvist C, Boriani G, Goette A, Kowey P, Merino JL, Piccini JP, Saksena S, Camm A J. Use of the “Pill in the Pocket” Approach for Atrial Fibrillation Termination as Determined from the Antiarrhythmic Interventions for Managing Atrial Fibrillation (AIM-AF) Study: A Physician Survey on the Prescription of Antiarrhythmic Drugs in the US and Europe.Presented at the Annual Scientific Sessions, American Heart Association, 2021. Circulation epub Circulation. 2021;144:A10986

Saksena S Blomström-Lundqvist C, Merino JL Goette A, Boriani G Kowey PR, Piccini JP, Reiffel JA, Camm AJ. Antiarrhythmic medication for atrial fibrillation (AIM-AF) study: a physician survey of ablation and antiarrhythmic drug use in the USA and Europe. , Heart Rhythm Vol. 18Issue 8SupplementS235

2022

Saksena, S, Slee, A. Adverse Cardiovascular Outcomes In Heart Failure (HF) With Preserved Systolic Function Associated With Atrial Fibrillation Are Due To Loss Of Rhythm Control Impacting HF Status: A Propensity Score Matched Analysis Of The TOPCAT Americas Study. Moderated poster presentation. 2022 American Heart Association, Chicago, IL, USA. Circulation. 2022;146:A12553

Slee A, Nagarakanti R, Saksena S. Do Natriuretic Peptide Measurements have prognostic value for Cardiovascular Events in AF with coexisting heart failure with preserved Ejection Fraction? Poster presentation. 2022 Heart Rhythm Society, San Francisco, CA, USA. Heart Rhythm 2022:19(5):S335

2023

Nagarakanti, R, Slee, A, Shah, D, Lewalter, T, Karcnik, J, Galgocy, S, Rochetter, M, Saksena, S. Atrial fibrillation is an independent risk factor for heart failure progression and pump failure mortality in HFpEF: a propensity score matched analysis of the TOPCAT Americas study. Accepted Moderated poster presentation. 2023 European Heart Rhythm Association, Barcelona, Spain. Europace 2023:

Nagarakanti R, Saksena S, Slee A, Natale A, Lakkireddy DJ, Shah D, Lewalter T, Santangeli P, DiBiase L: Atrial fibrillation can adversely affect heart failure with preserved ejection fraction by its association with heart failure progression in early stages and pump failure death in advanced heart failure. A TOPCAT sub study. Presented at the Annual Scientific Sessions, Heart Rhythm Society, May 2023. Heart Rhythm J. 2023: 20:E153

Saksena S, Ken-Opurum J, McKindley DS, Preblick R, Rashkin J, Aldaas OM, Sistla SSS, Hsu JC: Characteristics and predictors of repeat ablation in patients with atrial fibrillation undergoing multiple ablation procedures in real-world clinical practice. Presented at the Late Breaking Clinical Science, European Society of Cardiology, Amsterdam, 2023. ESC365: escardio.org/presentation/272300

Nagarakanti R, Slee A, Saksena S: Sudden death in heart failure with preserved ejection fraction: Role of atrial fibrillation and heart failure NYHA class: Presented at the Annual Scientific Sessions, American Heart Association. Philadelphia, November 2023. Circulation. 2023;148:A18143

2024

Natale A, Saksena S: Sustained reduction in left heart filling pressures in patients with heart failure with preserved ejection fraction using a rhythm control strategy incorporating catheter ablation. Presented at at the Annual Scientific Sessions of the Heart Rhythm Society 2024. Heart Rhythm Journal 2024: 21(5) S27-28

Slee A, Saksena S: Bundle branch block is independently associated with adverse cardiovascular outcomes in patients with heart failure with preserved ejection fraction:a propensity score matched analysis. Presented at the Annual Scientific Sessions, American Heart Association, November 2024, Chicago, Ill. Circulation 2024: 150 ( supplement 1): https://doi.org/10.1161/circ.150.suppl_1.4137695

2025

Slee A, Saksena S: Bundle branch block is independently associated with adverse cardiovascular outcomes in patients with heart failure with preserved ejection fraction:a propensity score matched analysis. Presented at the Annual Congress, European Heart Rhythm Association, 2025. Vienna, Austria

Slee A, Nagarakanti R, Saksena S: : Independent adverse impact of specific comorbidities on heart failure in patients with atrial fibrillation and heart failure wiith preserved ejection fraction: a TOPCAT Americas substudy. Presented at the Heart Rhythm Society meeting, San Diego, CA April , 2025. Heart Rhythm, 2025: Volume 22, Issue 4, S534